Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 844-851

  Liao, Bing ^a   Zhong, Bi Ling ^b   Li, Zhi ^a   Tian, Xiao Ying ^c   Li, Yang ^a   Li, Bin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b People's Hospital of Guangdong Province   (China)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

angiogenesis; Interleukin 8; macrophage migration inhibitory factor (MIF); nasopharyngeal carcinoma (NPC); prognosis

Indexed keywords

INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; UPREGULATION;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-8; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHATIC METASTASIS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 78649644727     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21728     Document Type: Article

References (42)

1. Yu MC, Yuan JM:, Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 421-429.
2. Farias TP, Dias FL, Lima RA, et al.: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129: 794-799.
3. Sakata K, Hareyama M, Tamakawa M, et al.: Prognostic factors of nasopharynx tumors investigated by MR imaging and the value of MR imaging in the newly published TNM staging. Int J Radiat Oncol Biol Phys 1999; 43: 273-278.
4. Tatsumi-Tamori A, Yoshizaki T, Miwa T, et al.: Clinical evaluation of staging system for nasopharyngeal carcinoma: Comparison of fourth and fifth editions of UICC TNM classification. Ann Otol Rhinol Laryngol 2000; 109: 1125-1129.
5. Fang W, Li X, Jiang Q, et al.: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 2008; 6: 32.
6. Feng XP, Yi H, Li MY, et al.: Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 2010; 70: 3450-3462.
7. Bach JP, Rinn B, Meyer B, et al.: Role of MIF in inflammation and tumorigenesis. Oncology 2008; 75: 127-133.
8. Krockenberger M, Engel JB, Kolb J, et al.: Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol 2010; 136: 651-657.
9. Rendon BE, Roger T, Teneng I, et al.: Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 2007; 282: 29910-29918.
10. Xu X, Wang B, Ye C, et al.: Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008; 261: 147-157. (Pubitemid 351253721)
11. Hira E, Ono T, Dhar DK, et al.: Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103: 588-598.
12. Bach JP, Deuster O, Balzer-Geldsetzer M, et al.: The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009; 115: 2031-2040.
13. Li GQ, Xie J, Lei XY, et al.: Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway. World J Gastroenterol 2009; 15: 5541-5548.
14. Lue H, Thiele M, Franz J, et al.: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26: 5046-5059.
15. Yu DS, Lin JC, Hsieh DS, et al.: Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer. Arch Androl 2006; 52: 283-291.
16. Legendre H, Decaestecker C, Nagy N, et al.: Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 2003; 16: 491-504.
17. Meyer-Siegler KL, Bellino MA, Tannenbaum M:, Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 2002; 94: 1449-1456.
18. Ren Y, Law S, Huang X, et al.: Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 2005; 242: 55-63.
19. White ES, Flaherty KR, Carskadon S, et al.: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: Role in angiogenesis and prognosis. Clin Cancer Res 2003; 9: 853-860.
20. Li Z, Ren Y, Wu QC, et al.: Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. Chin Med J (Engl) 2004; 117: 107-114.
21. Waugh DJ, Wilson C:, The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
22. Thelen A, Scholz A, Benckert C, et al.: Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. J Gastroenterol 2008; 43: 959-966.
23. Rubio L, Burgos JS, Lopez-Guerrero JA, et al.: Expression of p53 protein and tumor angiogenesis as prognostic factors in nasopharyngeal carcinoma patients. Pathol Res Pract 2002; 198: 97-102.
24. Foote RL, Weidner N, Harris J, et al.: Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: Results of RTOG 9505. Int J Radiat Oncol Biol Phys 2005; 61: 745-753.
25. Li Z, Bian LJ, Li Y, et al.: Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: Correlation with clinicopathological features and prognosis. Pathol Res Pract 2009; 205: 542-550.
26. Xu L, Pathak PS, Fukumura D:, Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase signling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res 2004; 10: 701-707.
27. Maxwell PJ, Gallagher R, Seaton A, et al.: HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007; 26: 7333-7345.
28. Yoshizaki T, Horikawa T, Ren QC, et al.: Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res 2001; 7: 1946-1951. (Pubitemid 32994829)
29. Hsu M, Wu SY, Chang SS, et al.: Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol 2008; 82: 3679-3688.
30. Min H, Hong M, Ma J, et al.: A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys 1994; 30: 1037-1042.
31. Kallioniemi OP, Wagner U, Kononen J, et al.: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657-662.
32. Li-juan B, Bing L, Zhi L, et al.: Hepatocyte growth factor suppresses tumor cell apoptosis in nasopharyngeal carcinoma by upregulating Bcl-2 protein expression. Pathol Res Pract 2009; 205: 828-837.
33. Xie LQ, Bian LJ, Li Z, et al.: Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep 2010; 23: 141-150.
34. Rubio L, Burgos JS, Morera C, et al.: Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients. Pathol Oncol Res 2000; 6: 210-216.
35. Carmeliet P, Jain RK:, Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
36. Chesney J, Metz C, Bacher M, et al.: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999; 5: 181-191.
37. Ren Y, Tsui HT, Poon RT, et al.: Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 2003; 107: 22-29.
38. Sun B, Nishihira J, Yoshiki T, et al.: Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res 2005; 11: 1050-1058.
39. Cacev T, Radosevic S, Krizanac S, et al.: Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008; 29: 1572-1580.
40. Caruso DJ, Carmack AJ, Lokeshwar VB, et al.: Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 2008; 14: 4111-4118.
41. Dong G, Chen Z, Li ZY, et al.: Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001; 61: 5911-5918.
42. Chiang YY:, Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells. Mol Carcinog 2009; 48: 662-670.